Introduction Principles of Sustainable Drug Discovery Giants Leading the Way Conclusion References
Sustainability in pharmaceutical development and marketing is crucial for human welfare since the use and role played by medicines will only increase as the human lifespan increases, and greater numbers of people live out their lifespans. Unless these medicines are produced ethically and greenly, the planet will come under greater environmental stress. Ironically, this will compromise long-term health through multiple mechanisms, such as antimicrobial resistance and fertility disorders.
Sustainability is defined by the Brundtland Commission of the United Nations as "development that meets the needs of the present without compromising the ability of future generations to meet their own needs." The greatest challenge of sustainability in pharmaceutical development is the complexity of the problem without a defined set of simple solutions. Moreover, these solutions are neither true nor false but may be classified as worse or better.
Image Credit: petrmalinak/Shutterstock.com
Researchers have put forward several essential principles in sustainable drug discovery. These include:
Benign-by-design also includes using the waste from one process as the raw material for the next. Pharmaceutical companies can minimize the use of resources by avoiding waste and redundancy. Moreover, modular design can help segregate those parts of the device that need to be incinerated from recyclable parts.
Packaging material can also be switched from non-biodegradable plastics to plastic from sugarcane or corn, for example, which completely degrades in about a decade. Biodegradable polyvinyl chloride (PVC), polycaprolactone (PCL), polybutylene adipate terephthalate (PBAT), and polylactic acid are all being explored for such use, to form at least the majority of the packaging, even if not all.
"For example, natural fibre based pulps, such as cellulose, cotton or bamboo, providing the rigid structure of a package, coupled to a film of polypropylene (PP) or polyethylene terephthalate (PET) that can provide the moisture-proofing, gas permeability or other properties to the composite while still being up to 99% recyclable,"
Mayur Patel and Eoin Sheridan
Paper inserts and manuals can be replaced by smart labels and augmented reality (AR) instructions on how to use drugs or medications by a simple QR code. The cold chain can be enhanced by using smart technology to operate just-in-time supply chain technology.
Novo Nordisk is an outstanding instance of how sustainable pharmaceuticals can be produced. Using a Circular for Zero strategy, this Swedish giant has designed a framework whereby its diabetes products, such as injection pens and medications, are designed to last the entire expected lifetime of the product, are made using sustainable materials, without production waste, and with post-use recycling and repurposing in mind.
"To give the pens a second life and prevent them from ending up in a landfill, Novo developed a system that sorts the insulin pens' many parts. From there, they were able to partner with a Danish design firm to make office chairs with the discarded plastic and lamps from the discarded glass insulin vials."
All its device development projects operate on this basis, using the indicators of CO2 impact per patient per year, the proportion of sustainable plastic used, and the product's recyclability at the end of its life as the measure of how good the development process is in terms of circularity.
AstraZeneca, a UK-Swedish pharmaceutical, is among the few giants in this area to invest heavily in cutting emissions while centering its sustainability program around equitable healthcare access, environmental protection, and transparent, ethical operations. It has received a double-A rating for four successive years for its environmental responsibility by the global organization CDP. Its Ambition Zero Carbon aims to move forward the date of zero carbon emissions by ten years, with an investment of one billion dollars to help meet these targets.
GlaxoSmithKline (GSK) has pledged itself to help produce affordable products over a larger market range while reducing emissions and water use in its operations. It has pledged carbon neutrality by 2030, as has Novartis. Biogen has already allotted $250 million to move entirely into renewable energy by 2050.
Sanofi, a French pharmaceutical, has reached a milestone in its aim to recycle, reuse or recover the waste produced during drug development, with the current level being 73%, not far down from its 2025 goal of 90%. The Japanese company Takeda has cut carbon emissions by more than a third relative to the 2005 levels. It aims to achieve carbon neutrality by 2040, cutting out greenhouse gas emissions completely by that point in its plants and helping suppliers cut their emissions.
Bayer has turned to green packaging as its core focus for the time being. This company has promised to achieve zero emissions of greenhouse gases by 2050. It is attempting to reduce its carbon emissions by switching to green packaging for all over-the-counter drugs from its consumer health division by the end of the current decade.
This means investing 100 million euros – 2% of the sales from this division. More ambitiously, it aims to use at least 50% recycled content and only sustainably produced paper, for its brand packaging, by 2050.
Image Credit: Francesco Scatena/Shutterstock.com
Pharmaceuticals need to be vigilant about their environmental impact, the effectiveness of healthcare mediated by medicine use, and the sustainability of pharmaceutical practices, from development, manufacture, marketing, use, and disposal/excretion of drugs. Integrating the available array of synthetic, computational, bioinformatics, metabolomics, and pharmacogenetics research and technologies, it should be possible to understand the forces shaping the future of pharmaceuticals in the current circumstances and to make the required changes to ensure a sustainable system that reduces the environmental footprint of pharmaceuticals.
News-Medical speaks to Henry Fingerhut, Senior Policy Analyst for Science & Innovation at the Tony Blair Institute for Global Change, about genomic surveillance and its associated opportunities and challenges.
Dr. Chenqu Suo and Dr. Cecilia Domínguez Conde
In this interview, News-Medical speaks to two researchers each discussing their respective studies that have contributed to the Human Cell Atlas; Dr. Chenqu Suo and Dr. Cecilia Domínguez Conde from the Wellcome Sanger Institute.
Irene Walsh and Professor Claire Smith
In this interview, News Medical speak to Irene Walsh, the director of Product, Design & Content, and 3D4Medical at Elsevier, and Professor Claire Smith, Head of Anatomy at Brighton and Sussex Medical School, about the real-world applications of the Complete Anatomy female model, the most advanced full female anatomy model in the world.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This site complies with the HONcode standard for trustworthy health information: verify here.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2022